The effect of RANKL and OPG on bone mineral density in pre-dialysis chronic renal failure

Clinical Nephrology

Volumn 71, Issue 6, 2009, Pages 652-659

  Fahrleitner Pammer, A ^a   Dobnig, H ^a   Dimai, H P ^a   Holzer, H ^a   Benesch, T ^b   Borchhardt, K ^b   Cejka, D ^b   Haas, Martin ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bone mineral density; Chronic renal failure; OPG; RANK; RANKL

Indexed keywords

25 HYDROXYVITAMIN D; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CALCITRIOL; CALCIUM; ESTRADIOL; FOLLITROPIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHATASE; SEX HORMONE; VITAMIN D; BIOLOGICAL MARKER; LUTEINIZING HORMONE; TESTOSTERONE;

ADULT; ARTICLE; BODY MASS; BONE DENSITY; CALCIUM BLOOD LEVEL; CELL ACTIVITY; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; ESTRADIOL BLOOD LEVEL; FEMALE; FEMORAL NECK Z SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OSTEOBLAST; OSTEOCLAST; PARATHYROID DISEASE; PHOSPHATE BLOOD LEVEL; SCORING SYSTEM; TROCHANTER Z SCORE; VITAMIN D DEFICIENCY; AGED; BLOOD; CROSS-SECTIONAL STUDY; FEMUR; GLOMERULUS FILTRATION RATE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; BONE DENSITY; CROSS-SECTIONAL STUDIES; FEMALE; FEMUR; FOLLICLE STIMULATING HORMONE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; LUTEINIZING HORMONE; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PARATHYROID HORMONE; RANK LIGAND; TESTOSTERONE; VITAMIN D;

EID: 67651009376     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP71652     Document Type: Article

References (36)

1. Avbersek-Luznik I, Balon BP, Rus I, Marc J. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? Nephrol Dial Transplant. 2005; 20: 566-570.
2. Barnas U, Schmidt A, Seidl G et al. A comparison of quantitative computed tomography and dual X-ray absorptiometry for evaluation of bone mineral density in patients on chronic hemodialysis. Am J Kidney Dis. 2001; 37: 1247-1252.
3. Bekker PJ, Holloway D, Nakanishi A et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res. 2001; 16: 348-360.
4. Bergh JJ, Xu Y, Farach-Carson MC. Osteoprotegerin expression and secretion are regulated by calcium influx through the L-type voltage-sensitive calcium channel. Endocrinology. 2004; 145: 426-436.
5. Bianchi ML, Colantonio G, Montesano A et al. Bone mass status in different degrees of chronic renal failure. Bone. 1992; 13: 225-228.
6. Body JJ, Greipp P, Coleman RE et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer. 2003; 97: 887-892.
7. Bonnick SL. Skeletal anatomy in densitometry in: Bone densitometry in clinical practice; application and interpretation (ed2), chap 2. Totowa, NJ: Humana Press; 2004. p. 29-67.
8. Boyle WJ, Simonet WA, Lacey D. Osteoclast differentiation and activation. Nature. 2003; 423: 337-342.
9. Brown JP, Prince RL, Deal C et al. Comparison of the effect of denusomab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2008; Sep 3 [Epub ahead of print].
10. Coen G, Mantella D, Manni M et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant. 2002; 17: 233-238.
11. Crisafulli A, Romeo A, Floccari F et al. Osteoprotegerin and bone mineral density in hemodiafiltration patients. Ren Fail. 2005; 27: 531-539.
12. Coen G, Bonucci E, Ballanti P et al. PTH 1-84 and PTH'7-84′ in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis. 2002; 40: 348-354.
13. Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in biphosphonate treated osteoporotic patients. Osteoporosis Int. 2006; 17: 693-703.
14. Doumouchtsis KK, Kostakis AI, Doumouchtsis SK et al. Associations between osteoprotegerin and femoral neck BMD in hemodialysis patients. J Bone Miner Metab. 2008; 26: 66-72.
15. Dovio A, Data V, Angeli A. Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice? J Endocrinol Invest. 2005; 28: 14-22.
16. Gomes SA, Dos Reis LM, de Oliveira IB et al. Usefulness of a quick decalcification of bone sections embedded in methyl metacrylate: an improved method for immunohistochemistry. J Bone Miner Metab. 2008; 26: 110-113.
17. Haas M, Leko-Mohr Z, Roschger P et al. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis. 2002; 39: 580-586.
18. Huang JC, Sakata T, Pfleger LL et al. PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res. 2004; 19: 235-244.
19. Jamal SA, Hayden JA, Beyene J. Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis. Am J Kidney Dis. 2007; 49: 674-681.
20. Kazama JJ, Shigematsu T, Yano K et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis. 2002; 39: 525-532.
21. 3 - stimulate formation in spleen-osteoblast cocultures and is mediated in part by enhanced Il-1α and receptor activator of NF-κB ligand production in osteoblasts. J Immunol. 2002; 169: 2374-2238.
22. Liu JM, Zhao HY, Ning G et al. Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75. Calcif Tissue Int. 2005; 76:1-6.
23. Malluche HH, Ritz E, Lange HP et al. Bone histology in incipient and advanced renal failure. Kidney Int. 1976; 9: 355-362.
24. Malluche HH, Koszewski N, Monier-Faugere MC, Williams JP, Mawad H. Influence of the parathyroid glands on bone metabolism. Eur J Clin Invest. 2006; 36: 23-33.
25. Malyszko J, Malyszko JS, Wolczynski S, Mysliwiec M. Osteoprotegerin and its correlations with new markers of bone formation and bone resorption in kidney transplant recipients. Transplant Proc. 2003; 35: 2227-2229.
26. Monier-Faugere MC, Geng Z, Mawad H et al. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int. 2001; 60: 1460-1468.
27. National Kidney Foundation. K/OQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39 (Suppl 1): S1-S266.
28. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int. 1999; 56: 1084-1093.
29. Sato T, Tominaga Y, Iwasaki Y et al. Osteoprotegerin levels before and after renal transplantation. Am J Kidney Dis. 2001; 38: S175-S177.
30. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89: 309-319.
31. Stern A, Laughlin GA, Bergstrom J, Barrett-Connor E. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB ligand with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol. 2007; 156: 555-562.
32. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signalling in osteoclastogenesis and bone disease. Trends Mol Med. 2006; 12: 17-25.
33. Wittersheim E, Mesquita M, Demulder A et al. OPG, RANKL, bone metabolism, and BMD in patients on peritoneal dialysis and hemodialysis. Clin Biochem. 2006; 39: 617-622.
34. Weisinger JR, Gonzales L, Alvarez H et al. Role of persistent amenorrhea in bone mineral metabolism of young hemodialyzed women. Kidney Int. 2000; 58: 331-335.
35. Yasuda H, Shima N, Nakagawa N et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis - inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci. 1998a; 95: 3597-3602.
36. Yasuda H, Shima N, Nakagawa N et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998b; 139: 1329-1337.